These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20048699)

  • 21. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire.
    Parsons MS; Rouleau D; Routy JP; LeBlanc R; Grant MD; Bernard NF
    AIDS; 2011 Jun; 25(10):1249-64. PubMed ID: 21516028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies.
    Sun Z; Yan L; Tang J; Qian Q; Lenberg J; Zhu D; Liu W; Wu K; Wang Y; Lu S
    Virus Res; 2018 Jan; 243():75-82. PubMed ID: 29051051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV vaccine development--improving on natural immunity.
    Johnston MI; Fauci AS
    N Engl J Med; 2011 Sep; 365(10):873-5. PubMed ID: 21899447
    [No Abstract]   [Full Text] [Related]  

  • 25. Paradoxical suppression of poly-specific broadly neutralizing antibodies in the presence of strain-specific neutralizing antibodies following HIV infection.
    Ciupe SM; De Leenheer P; Kepler TB
    J Theor Biol; 2011 May; 277(1):55-66. PubMed ID: 21315731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current world literature.
    Curr Opin HIV AIDS; 2009 Sep; 4(5):453-7. PubMed ID: 20046137
    [No Abstract]   [Full Text] [Related]  

  • 27. Study describes onset of broadly neutralizing antibody responses in HIV-infected individuals.
    von Bubnoff A
    IAVI Rep; 2011; 15(1):23. PubMed ID: 21449508
    [No Abstract]   [Full Text] [Related]  

  • 28. HIV infection and specific mucosal immunity: workshop 4B.
    Challacombe SJ; Fidel PL; Tugizov S; Tao L; Wahl SM
    Adv Dent Res; 2011 Apr; 23(1):142-51. PubMed ID: 21441496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 phylogenetics and vaccines.
    Rolland M
    Curr Opin HIV AIDS; 2019 May; 14(3):227-232. PubMed ID: 30925535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Approaches to the induction of HIV broadly neutralizing antibodies.
    Moore PL; Williamson C
    Curr Opin HIV AIDS; 2016 Nov; 11(6):569-575. PubMed ID: 27559709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers.
    van den Kerkhof TL; Euler Z; van Gils MJ; Boeser-Nunnink BD; Schuitemaker H; Sanders RW
    AIDS; 2014 May; 28(8):1237-40. PubMed ID: 24556870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lessons learned from humoral responses of HIV patients.
    McCoy LE; McKnight Á
    Curr Opin HIV AIDS; 2017 May; 12(3):195-202. PubMed ID: 28422783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV.
    Ali Tabei SM; Li Y; Weigert M; Dinner AR
    Vaccine; 2012 Jan; 30(3):607-13. PubMed ID: 22119591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Broadly Neutralizing Antibodies: Magic Bullets against HIV?
    Julg B; Alter G
    Immunity; 2016 Jun; 44(6):1253-4. PubMed ID: 27332729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying broadly neutralizing antibody activity in HIV-infected individuals.
    Kresge KJ
    IAVI Rep; 2009; 13(3):18. PubMed ID: 20214321
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of broadly neutralizing antibodies for HIV-1 prevention.
    Pegu A; Hessell AJ; Mascola JR; Haigwood NL
    Immunol Rev; 2017 Jan; 275(1):296-312. PubMed ID: 28133803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals.
    Euler Z; van Gils MJ; Boeser-Nunnink BD; Schuitemaker H; van Manen D
    PLoS One; 2013; 8(1):e54684. PubMed ID: 23372753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Research. 'Superinfected' have more potent antibody response to HIV.
    AIDS Policy Law; 2012 May; 27(6):3. PubMed ID: 22655314
    [No Abstract]   [Full Text] [Related]  

  • 39. Broadly neutralizing antibodies to prevent HIV-1.
    Cohen MS; Corey L
    Science; 2017 Oct; 358(6359):46-47. PubMed ID: 28983040
    [No Abstract]   [Full Text] [Related]  

  • 40. The humoral response to HIV-1: new insights, renewed focus.
    Alter G; Moody MA
    J Infect Dis; 2010 Oct; 202 Suppl 2(Suppl 2):S315-22. PubMed ID: 20846039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.